These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 38273367)

  • 1. Prognostic significance and survival benefits of postoperative adjuvant chemotherapy in patients with stage IA lung adenocarcinoma with non-predominant micropapillary components.
    Li R; Qiu J; Li Z; Li H; Tang Z; Yu W; Tian H; Sun Z
    World J Surg Oncol; 2024 Jan; 22(1):32. PubMed ID: 38273367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of postoperative adjuvant therapy on EGFR-mutated stage IA lung adenocarcinoma with micropapillary pathological subtypes.
    Cheng R; Hao Z; Qiu L; Zheng X; Huang S; Xian J; Huang H; Li J; Zhang Z; Ye K; Wu W; Zhang Y; Liu J
    World J Surg Oncol; 2024 Sep; 22(1):235. PubMed ID: 39232762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic significance and adjuvant chemotherapy survival benefits of a solid or micropapillary pattern in patients with resected stage IB lung adenocarcinoma.
    Qian F; Yang W; Wang R; Xu J; Wang S; Zhang Y; Jin B; Yu K; Han B
    J Thorac Cardiovasc Surg; 2018 Mar; 155(3):1227-1235.e2. PubMed ID: 29223834
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survival benefit of adjuvant chemotherapy after resection of Stage I lung adenocarcinoma containing micropapillary components.
    Li Y; Zhao J; Zhao Y; Li R; Dong X; Yao X; Xia Z; Xu Y; Li Y
    Cancer Med; 2024 Feb; 13(3):e7030. PubMed ID: 38400663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Micropapillary Predominant Lung Adenocarcinoma in Stage IA Benefits from Adjuvant Chemotherapy.
    Wang C; Yang J; Lu M
    Ann Surg Oncol; 2020 Jun; 27(6):2051-2060. PubMed ID: 31848813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of surgery and adjuvant chemotherapy on the survival of stage I lung adenocarcinoma patients with tumor spread through air spaces.
    Lv Y; Li S; Liu Z; Ren Z; Zhao J; Tao G; Zheng Z; Han Y; Ye B
    Lung Cancer; 2023 Mar; 177():51-58. PubMed ID: 36736075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Validation of prognostic value of pathological staging in pathological stage Ⅰ lung adenocarcinoma].
    Zhang H; Sun FH; Chen ZC; Wang Q
    Zhonghua Wai Ke Za Zhi; 2022 Jun; 60(6):580-586. PubMed ID: 35658346
    [No Abstract]   [Full Text] [Related]  

  • 8. Does the presence of a micropapillary component predict worse prognosis in pathological stage IA lung adenocarcinoma?
    Wang Y; Song W; Wang X; Che G
    Pathol Res Pract; 2023 Feb; 242():154314. PubMed ID: 36706587
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A prognostic nomogram based on a new classification of combined micropapillary and solid components for stage IA invasive lung adenocarcinoma.
    Huang W; Zhang H; Zhang Z; Zhang B; Sun X; Huo Y; Feng Y; Tian P; Mo H; Wang C
    J Surg Oncol; 2022 Mar; 125(4):796-808. PubMed ID: 34862621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Association between the presence of solid or micropapillary components and survival outcome in stage ⅠA lung adenocarcinoma cases: a retrospective cohort study].
    Jin KQ; Shen YR; Wu YM; Dai J; Liu XG; Li JQ; Chen LS; Jiang GN
    Zhonghua Wai Ke Za Zhi; 2022 Jun; 60(6):587-592. PubMed ID: 35658347
    [No Abstract]   [Full Text] [Related]  

  • 11. Prognostic and predictive value of the novel classification of lung adenocarcinoma in patients with stage IB.
    Luo J; Huang Q; Wang R; Han B; Zhang J; Zhao H; Fang W; Luo Q; Yang J; Yang Y; Zhu L; Chen T; Cheng X; Wang Y; Zheng J; Wu H; Xia W; Chen H
    J Cancer Res Clin Oncol; 2016 Sep; 142(9):2031-40. PubMed ID: 27379889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Micropapillary or solid component predicts worse prognosis in pathological IA stage lung adenocarcinoma: A meta-analysis.
    Wang Y; Hu J; Sun Y; Lu Y
    Medicine (Baltimore); 2023 Dec; 102(49):e36503. PubMed ID: 38065873
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Who benefit from adjuvant chemotherapy in stage I lung adenocarcinoma? A multi-dimensional model for candidate selection.
    Jiang MQ; Qian LQ; Shen YJ; Fu YY; Feng W; Ding ZP; Han YC; Fu XL
    Neoplasia; 2024 Apr; 50():100979. PubMed ID: 38387107
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Value of adjuvant chemotherapy for patients with pT2N0M0 non-small cell lung cancer receiving radical resection.
    Chen S; Yang S; Zhao Y; Zhang Y; Huang Q; Wu H; Hu H; Sun Y; Zhang Y; Xiang J; Ye T; Chen H
    Thorac Cancer; 2024 Jan; 15(3):258-265. PubMed ID: 38098268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Selection of postoperative adjuvant therapy for patients with stage IB lung adenocarcinoma: analysis of 653 cases].
    Shen L; Chen Y; Yun T; Guo J; Liu X; Zhang T; Liang C; Liu Y
    Nan Fang Yi Ke Da Xue Xue Bao; 2024 May; 44(5):989-997. PubMed ID: 38862458
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A Review on Pathological High-risk Factors and Postoperative Adjuvant Chemotherapy in Stage IA Lung Adenocarcinoma].
    Shen C; Fang W
    Zhongguo Fei Ai Za Zhi; 2022 Aug; 25(8):593-600. PubMed ID: 36002196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-risk characteristics of pathological stage I lung adenocarcinoma after resection: patients for whom adjuvant chemotherapy should be performed.
    Wu LL; Jiang WM; Qian JY; Tian JY; Li ZX; Li K; Ma GW; Xie D; Chen C
    Heliyon; 2023 Dec; 9(12):e23207. PubMed ID: 38144332
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant chemotherapy in patients with recurrence after completely resected stage IB lung adenocarcinoma: Propensity-matched analysis in a cohort of 147 recurrences.
    Xu F; Chen HC; Xu H; Li J; Hao X; Xing P; Ying J; Wang Y
    Thorac Cancer; 2022 Nov; 13(22):3105-3113. PubMed ID: 36104006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive Value of Recurrence of Solid and Micropapillary Subtypes in Lung Adenocarcinoma.
    Motono N; Mizoguchi T; Ishikawa M; Iwai S; Iijima Y; Uramoto H
    Oncology; 2024; 102(4):366-373. PubMed ID: 37899040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Both the presence of a micropapillary component and the micropapillary predominant subtype predict poor prognosis after lung adenocarcinoma resection: a meta-analysis.
    Wang W; Hu Z; Zhao J; Huang Y; Rao S; Yang J; Xiao S; Cao R; Ye L
    J Cardiothorac Surg; 2020 Jun; 15(1):154. PubMed ID: 32600473
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.